SCHEMBL5148377

SCHEMBL5148377

CCCN(CCC)c1cc2c(cc1C(C)N(Cc1cccc(Cl)c1)C(=O)O)CCC2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.39
SLC2A1 P11166 2/20 0.39
PTGES O14684 1/20 0.38
TSHR P16473 1/20 0.38
RECQL P46063 1/20 0.38
WDR5 P61964 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
RORC P51449 1/20 0.36
UBE2M P61081 2/20 0.36
DCUN1D1 Q96GG9 2/20 0.36
HTT P42858 1/20 0.36
LIMK1 P53667 1/20 0.36
LIMK2 P53671 1/20 0.36
GHSR Q92847 2/20 0.35
TMEM97 Q5BJF2 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
CRHR1 P34998 1/20 0.35
TAS2R14 Q9NYV8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5151018 0.85 SLC6A2 (0.39) PTGESRORCDCUN1D1NR3C1
SCHEMBL5670858 0.81 LIMK1 (0.40) RIPK1SLC2A1PTGESTSHRALDH1A1
SCHEMBL5150322 0.79 TACR1 (0.40) PTGESUBE2MDCUN1D1TMEM97SIGMAR1
SCHEMBL5148332 0.79 SERPINE1 (0.37) TSHRUBE2MDCUN1D1
SCHEMBL5148370 0.76 PSEN1 (0.36) UBE2MDCUN1D1
SCHEMBL5148327 0.75 SERPINE1 (0.36) TSHRUBE2MDCUN1D1
SCHEMBL1902779 0.74 HTT (0.39) RIPK1SLC2A1PTGESTSHRALDH1A1
SCHEMBL1906692 0.74 UBE2M (0.34) L3MBTL1UBE2MDCUN1D1HTTCRHR1
SCHEMBL2262702 0.73 CHRM5 (0.35) PTGESALDH1A1GAAUBE2MDCUN1D1
SCHEMBL5672100 0.73 TAAR1 (0.43) GAAHTTSIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070054839-A1 Method of inhibiting remnant lipoprotein production JAPAN TOBACCO INC. (JP) 2007-03-08 US claimed
US-20060270705-A1 Method for inhibiting lipid absorption and lipid absorption inhibitor JAPAN TOBACCO INC. (JP) 2006-11-30 US claimed
US-20070054839-A1 Method of inhibiting remnant lipoprotein production JAPAN TOBACCO INC. (JP) 2007-03-08 US disclosed
US-20060270705-A1 Method for inhibiting lipid absorption and lipid absorption inhibitor JAPAN TOBACCO INC. (JP) 2006-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054839-A1 Method of inhibiting remnant lipoprotein production CETP, PCSK9, LIPA RIPK1 1951/4885SLC2A1 2195/4885PTGES 1900/4885
US-20060270705-A1 Method for inhibiting lipid absorption and lipid absorption inhibitor CETP, SI, LIPC RIPK1 1782/4885SLC2A1 97/4885PTGES 806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.